New allergen patterns in beer allergy

15. August 2014

Experience shows that people who have an allergic reaction to beer are merely greeted with a grin from those around them. Nevertheless, these reactions can definitely be life-threatening. The prevalence of beer allergy in Germany is low. Therefore cooperation with Chongquing Medical University (China) and a CK-CARE exchange programme provided a useful opportunity to study 20 cases of anaphylaxis following beer consumption.

As well as detailed history-taking and clinical examination, skin tests were performed with 12 different materials. These originated from native beer production in collaboration with the Institute of Brewing and Beverage Technology at the Weihenstephan Science Centre of the Technical University of Munich (TUM) and comprised not only barley and barley malt but also sorghum, millet, maize and yeast, hops and enzymes, substances which are used in China but also in many countries around the world. Furthermore, various original types of beer were introduced into the tests. In addition, oral challenge tests were performed after the success of the skin testing.

75% of the patients showed positive reactions to at least one or more beer ingredients, most commonly to sorghum and sorghum malt. Seventeen patients reacted in the oral challenge with predominantly skin symptoms in the form of flush and urticaria, which lasted up to two hours. A total of 5 patients reacted to hops, 2 of them reacting solely to hops. Seven patients reacted to millet but frequently in concurrent reactions to barley or sorghum. One patient reacted to yeast in isolation. It may be concluded from these tests that beer allergy is not a simple phenomenon, but quite different ingredients in beer can trigger severe reactions. In conjunction with growing globalisation and the availability of foreign beer varieties, an increase in beer allergies might also be observed in Central Europe (Song et al 2013 in press). To pre-empt possible comments, we have also observed cases of anaphylactic reactions to grape juice and wine.

Spatial transcriptomics combined with single-cell RNA-sequencing unravels the complex inflammatory cell network in atopic dermatitis

6. September 2023

Atopic dermatitis (AD) is a chronic inflammatory skin disorder affecting up to 3%–5% of adults and 20% of children worldwide. The pathophysiology of AD involves various factors including host genetics, altered skin barrier function, and immunological abnormalities.

Atopic dermatitis: Correlation of distinct risk factors with age of onset in adulthood compared to childhood

14. June 2023

Atopic dermatitis (AD) has long been regarded as a primarily pediatric disease. However, there is growing evidence for a high rate of adult-onset AD. We aimed to characterize factors associated with adult-onset versus childhood-onset AD and controls.
An analysis of the CK-CARE-ProRaD cohort revealed adult-onset AD in nearly a quarter of patients. We identified active smoking to be associated with adult-onset AD versus controls. Food allergy, maternal food allergy, palmar hyper linearity, and academic background increased the odds of childhood-onset AD versus controls.

Shared AD-associated factors were maternal AD (4-34x), increased IgE (2-20x), atopic stigmata (2-3x) with varying effect sizes depending on AD onset and control group. Patients with adult-compared to childhood-onset had doubled odds of allergic rhinitis, but reduced odds to feature multiple (3-4) atopic comorbidities. Adult-onset AD, particularly onset ≥61 years, grouped mainly in clusters with low contributions of personal and familial atopy and high frequencies of physical inactivity, childhood-onset AD, particularly infant-onset, mainly in “high-atopic”-clusters.

The identified associated factors suggest partly varying endo- and exogeneous mechanisms underlying adult-onset versus childhood-onset AD. Our findings might contribute to better assessment of the individual risk to develop AD throughout life and encourage prevention by non-smoking and physical activity as modifiable lifestyle factors.

Certification by the Swiss Biobanking Platform – VITA-Label

7. November 2022

Building up a proper Governance through accountable mechanisms is key to foster trustworthiness and the pre-requisite for the appropriate use of biological resources. Our CK-CARE Biobank has recently been awarded by Swiss Biobanking Platform (SBP) with the VITA Label, which demonstrates compliance with the applicable legal and ethical framework. This labelling approach is part of our long-term strategy to strengthen biobanking practices and provide high-quality samples to the research community.

CK-CARE Team Meeting October 10th- 11th, 2022

17. October 2022

This year’s CK-CARE team event in Davos focused on strengthening cross-center communication and collaboration. Our team members got to know each other and the canton of Grisons better by producing several Grisons specialties as “cross-center team building” in preparation for the scientific work. This as a goal to promote teamwork! Although there was no knowledge about the production of Graubünden delicacies, let alone anyone with appropriate skills, each team excelled in its own way. Driven by trust, respect and genuine motivation to solve the tasks set, the team members met the challenge of working together with fun and creativity as an important preparation for the following day’s research activities. It was a successful meeting – we look forward to many more.

Certification by the Swiss Biobanking Platform – OPTIMA-Label

9. June 2022

Davos BioSciences AG achieved the official OPTIMA label of the Swiss Biobanking Platform for its biobank infrastructure as of 30.05.2022. This is another important step for Davos BioSciences AG and CK-CARE. The label attests to the full implementation of a QM system. The OPTIMA-Label confirms: “Compliance with the Good Biobanking Practices; in particular OECD Best practice guidelines for biological resource centres (2007), ISBER Best practices (2018) and IARC Common minimum technical standards (2017). It follows established standards, including the ISO 20387:2018 – general requirements for biobanking. This certification approach is part of our long-term strategy to provide high-quality samples to the research community”.

Certification by the Swiss Biobanking Platform

9. June 2022

After some effort, Davos BioSciences AG achieved the official NORMA label of the Swiss Biobanking Platform for its biobank infrastructure as of 17.08.2021. This is an important step for Davos BioSciences AG and CK-CARE. The NORMA-Label confirms: “Compliance with professional standards is essential to perform our daily biobanking activities according to Good Biobanking Practices; in particular OECD Best practice guidelines for biological resource centres (2007), ISBER Best practices (2018) and IARC Common minimum technical standards (2017). It follows established standards, including the ISO 20387:2018 – general requirements for biobanking. This certification approach is part of our long-term strategy to provide high-quality samples to the research community”. Certificate of the Swiss Biobanking Plattform